Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease

M. Libra, S. S. Signorelli, Y. Bevelacqua, P. M. Navolanic, V. Bevelacqua, J. Polesel, R. Talamini, F. Stivala, M. C. Mazzarino, G. Malaponte

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Aims: To determine whether the G(-174)C interleukin 6 (IL-6) polymorphism influences the development of peripheral arterial disease (PAD) in individuals with type 2 diabetes. This was investigated by comparing the distribution of G(-174)C genotypes between patients with type 2 diabetes and PAD (PAD +) and those with type 2 diabetes but without PAD (PAD-). Plasma concentrations of IL-6, fibrinogen, C reactive protein (CRP), and vascular endothelial growth factor (VEGF) were also compared in PAD+ and PAD- patients. Methods: Blood samples were collected from 146 PAD+ and 144 PAD- patients. SfaNI was used to determine the G(-174)C genotype. Plasma concentrations of IL-6, fibrinogen, CRP, and VEGF were measured by an enzyme linked immunosorbent assay. Results: The GG genotype was more common in PAD+ patients than in PAD- patients. PAD+ patients also had increased mean plasma concentrations of IL-6, fibrinogen, CRP, and VEGF compared with PAD- patients. Mean plasma concentrations of IL-6, fibrinogen, and CRP in both PAD+ and PAD - patients were higher in those with the GG genotype than in those with the GC or CC genotypes. In contrast, mean plasma concentrations of VEGF in PAD+ and PAD patients were not significantly different between those with different G(-174)C genotypes. Conclusions: These results support a model in which the GG genotype promotes PAD development among individuals with type 2 diabetes by inducing increased release of IL-6. Higher concentrations of IL-6 among those with the GG genotype is associated with increased plasma concentrations of fibrinogen and CRP.

Original languageEnglish
Pages (from-to)211-215
Number of pages5
JournalJournal of Clinical Pathology
Volume59
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Peripheral Arterial Disease
Type 2 Diabetes Mellitus
Interleukin-6
Genotype
C-Reactive Protein
Fibrinogen
Vascular Endothelial Growth Factor A

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. / Libra, M.; Signorelli, S. S.; Bevelacqua, Y.; Navolanic, P. M.; Bevelacqua, V.; Polesel, J.; Talamini, R.; Stivala, F.; Mazzarino, M. C.; Malaponte, G.

In: Journal of Clinical Pathology, Vol. 59, No. 2, 02.2006, p. 211-215.

Research output: Contribution to journalArticle

Libra, M, Signorelli, SS, Bevelacqua, Y, Navolanic, PM, Bevelacqua, V, Polesel, J, Talamini, R, Stivala, F, Mazzarino, MC & Malaponte, G 2006, 'Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease', Journal of Clinical Pathology, vol. 59, no. 2, pp. 211-215. https://doi.org/10.1136/jcp.2004.025452
Libra, M. ; Signorelli, S. S. ; Bevelacqua, Y. ; Navolanic, P. M. ; Bevelacqua, V. ; Polesel, J. ; Talamini, R. ; Stivala, F. ; Mazzarino, M. C. ; Malaponte, G. / Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. In: Journal of Clinical Pathology. 2006 ; Vol. 59, No. 2. pp. 211-215.
@article{812e0bc5d3bd41478ee22d6f3cb9c93e,
title = "Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease",
abstract = "Aims: To determine whether the G(-174)C interleukin 6 (IL-6) polymorphism influences the development of peripheral arterial disease (PAD) in individuals with type 2 diabetes. This was investigated by comparing the distribution of G(-174)C genotypes between patients with type 2 diabetes and PAD (PAD +) and those with type 2 diabetes but without PAD (PAD-). Plasma concentrations of IL-6, fibrinogen, C reactive protein (CRP), and vascular endothelial growth factor (VEGF) were also compared in PAD+ and PAD- patients. Methods: Blood samples were collected from 146 PAD+ and 144 PAD- patients. SfaNI was used to determine the G(-174)C genotype. Plasma concentrations of IL-6, fibrinogen, CRP, and VEGF were measured by an enzyme linked immunosorbent assay. Results: The GG genotype was more common in PAD+ patients than in PAD- patients. PAD+ patients also had increased mean plasma concentrations of IL-6, fibrinogen, CRP, and VEGF compared with PAD- patients. Mean plasma concentrations of IL-6, fibrinogen, and CRP in both PAD+ and PAD - patients were higher in those with the GG genotype than in those with the GC or CC genotypes. In contrast, mean plasma concentrations of VEGF in PAD+ and PAD patients were not significantly different between those with different G(-174)C genotypes. Conclusions: These results support a model in which the GG genotype promotes PAD development among individuals with type 2 diabetes by inducing increased release of IL-6. Higher concentrations of IL-6 among those with the GG genotype is associated with increased plasma concentrations of fibrinogen and CRP.",
author = "M. Libra and Signorelli, {S. S.} and Y. Bevelacqua and Navolanic, {P. M.} and V. Bevelacqua and J. Polesel and R. Talamini and F. Stivala and Mazzarino, {M. C.} and G. Malaponte",
year = "2006",
month = "2",
doi = "10.1136/jcp.2004.025452",
language = "English",
volume = "59",
pages = "211--215",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease

AU - Libra, M.

AU - Signorelli, S. S.

AU - Bevelacqua, Y.

AU - Navolanic, P. M.

AU - Bevelacqua, V.

AU - Polesel, J.

AU - Talamini, R.

AU - Stivala, F.

AU - Mazzarino, M. C.

AU - Malaponte, G.

PY - 2006/2

Y1 - 2006/2

N2 - Aims: To determine whether the G(-174)C interleukin 6 (IL-6) polymorphism influences the development of peripheral arterial disease (PAD) in individuals with type 2 diabetes. This was investigated by comparing the distribution of G(-174)C genotypes between patients with type 2 diabetes and PAD (PAD +) and those with type 2 diabetes but without PAD (PAD-). Plasma concentrations of IL-6, fibrinogen, C reactive protein (CRP), and vascular endothelial growth factor (VEGF) were also compared in PAD+ and PAD- patients. Methods: Blood samples were collected from 146 PAD+ and 144 PAD- patients. SfaNI was used to determine the G(-174)C genotype. Plasma concentrations of IL-6, fibrinogen, CRP, and VEGF were measured by an enzyme linked immunosorbent assay. Results: The GG genotype was more common in PAD+ patients than in PAD- patients. PAD+ patients also had increased mean plasma concentrations of IL-6, fibrinogen, CRP, and VEGF compared with PAD- patients. Mean plasma concentrations of IL-6, fibrinogen, and CRP in both PAD+ and PAD - patients were higher in those with the GG genotype than in those with the GC or CC genotypes. In contrast, mean plasma concentrations of VEGF in PAD+ and PAD patients were not significantly different between those with different G(-174)C genotypes. Conclusions: These results support a model in which the GG genotype promotes PAD development among individuals with type 2 diabetes by inducing increased release of IL-6. Higher concentrations of IL-6 among those with the GG genotype is associated with increased plasma concentrations of fibrinogen and CRP.

AB - Aims: To determine whether the G(-174)C interleukin 6 (IL-6) polymorphism influences the development of peripheral arterial disease (PAD) in individuals with type 2 diabetes. This was investigated by comparing the distribution of G(-174)C genotypes between patients with type 2 diabetes and PAD (PAD +) and those with type 2 diabetes but without PAD (PAD-). Plasma concentrations of IL-6, fibrinogen, C reactive protein (CRP), and vascular endothelial growth factor (VEGF) were also compared in PAD+ and PAD- patients. Methods: Blood samples were collected from 146 PAD+ and 144 PAD- patients. SfaNI was used to determine the G(-174)C genotype. Plasma concentrations of IL-6, fibrinogen, CRP, and VEGF were measured by an enzyme linked immunosorbent assay. Results: The GG genotype was more common in PAD+ patients than in PAD- patients. PAD+ patients also had increased mean plasma concentrations of IL-6, fibrinogen, CRP, and VEGF compared with PAD- patients. Mean plasma concentrations of IL-6, fibrinogen, and CRP in both PAD+ and PAD - patients were higher in those with the GG genotype than in those with the GC or CC genotypes. In contrast, mean plasma concentrations of VEGF in PAD+ and PAD patients were not significantly different between those with different G(-174)C genotypes. Conclusions: These results support a model in which the GG genotype promotes PAD development among individuals with type 2 diabetes by inducing increased release of IL-6. Higher concentrations of IL-6 among those with the GG genotype is associated with increased plasma concentrations of fibrinogen and CRP.

UR - http://www.scopus.com/inward/record.url?scp=32544459783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544459783&partnerID=8YFLogxK

U2 - 10.1136/jcp.2004.025452

DO - 10.1136/jcp.2004.025452

M3 - Article

VL - 59

SP - 211

EP - 215

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 2

ER -